EYEN Eyenovia Inc
Price (delayed)
$1.18
Market cap
$1.28M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$56.8
Enterprise value
$7.1M
Eyenovia, Inc. is a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP) therapeutics. Eyenovia is currently focused on the late-stage development of microdosed medications for
Highlights
Eyenovia's debt has decreased by 19% YoY and by 17% from the previous quarter
The EPS has contracted by 9% YoY but it has grown by 9% from the previous quarter
The company's quick ratio has shrunk by 86% YoY
The company's gross margin has shrunk by 80% YoY and by 24% QoQ
Key stats
What are the main financial stats of EYEN
Market
Valuations
Earnings
Shares outstanding
1.08M
Market cap
$1.28M
Enterprise value
$7.1M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.25
Price to sales (P/S)
32.23
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
223
Revenue
$31,832
Gross profit
-$583,469
Operating income
-$36.74M
Net income
-$37.83M
EBIT
-$35.2M
EBITDA
-$34.09M
Free cash flow
-$30.64M
Per share
Balance sheet
Liquidity
EPS
-$56.8
EPS diluted
-$56.8
Free cash flow per share
-$35.24
Book value per share
$4.64
Revenue per share
$0.04
TBVPS
$19.18
Total assets
$22.8M
Total liabilities
$19.08M
Debt
$13.01M
Equity
$3.72M
Working capital
-$4.09M
Debt to equity
3.5
Current ratio
0.74
Quick ratio
0.46
Net debt/EBITDA
-0.17
Margins
Efficiency
Dividend
EBITDA margin
-107,084.9%
Gross margin
-1,833%
Net margin
-118,845.2%
Operating margin
-115,413.7%
Return on assets
-156.4%
Return on equity
-1,243.8%
Return on invested capital
-295.1%
Return on capital employed
-501.9%
Return on sales
-110,566.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
EYEN stock price
How has the Eyenovia stock price performed over time
Intraday
4.42%
1 week
-6.35%
1 month
-30.18%
1 year
-98.47%
YTD
-89.9%
QTD
7.27%
Financial performance
How have Eyenovia's revenue and profit performed over time
Revenue
$31,832
Gross profit
-$583,469
Operating income
-$36.74M
Net income
-$37.83M
Gross margin
-1,833%
Net margin
-118,845.2%
Eyenovia's net margin has soared by 94% YoY
The operating margin has soared by 94% YoY
The company's gross margin has shrunk by 80% YoY and by 24% QoQ
EYEN's operating income has plunged by 58% YoY and by 2.3% from the previous quarter
Growth
What is Eyenovia's growth rate over time
Valuation
What is Eyenovia stock price valuation
P/E
N/A
P/B
0.25
P/S
32.23
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
223
The EPS has contracted by 9% YoY but it has grown by 9% from the previous quarter
EYEN's P/B is 97% below its 5-year quarterly average of 9.4
The company's equity has shrunk by 76% YoY
The P/S is 100% below the last 4 quarters average of 7476.3
Efficiency
How efficient is Eyenovia business performance
Eyenovia's ROIC has plunged by 146% YoY and by 33% from the previous quarter
The ROE has shrunk by 102% QoQ
The ROS has soared by 94% YoY
Eyenovia's ROA has plunged by 92% YoY and by 14% from the previous quarter
Dividends
What is EYEN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for EYEN.
Financial health
How did Eyenovia financials performed over time
The total assets is 19% greater than the total liabilities
The company's quick ratio has shrunk by 86% YoY
Eyenovia's current ratio has plunged by 82% YoY but it has soared by 61% from the previous quarter
Eyenovia's debt to equity has surged by 153% QoQ
The company's equity has shrunk by 76% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.